News of the Day

Some Australian-based companies are already assessing the risks of the 'Pelosi plan' with and contemplating whether they should delay the launch of new medicines to avoid the risk of withdrawal.

An official analysis of a new medicine pricing plan under consideration by the US Congress suggests it could halve the number of new medicines and ultimately undermine health outcomes.

The November PBS schedule update includes some new medicines and a large number of 'new or amended items'.

The 'tumour agnostic' therapy presents a new challenge to the PBS given the nature of trials and the likelihood companies may take different approaches to the assessment process.

"This is not easy because it requires significant focus and the investment of resources," she said, adding "we have to make choices and direct our time and energy towards what will deliver the best outcome for the health system," Ms Hood told BioPharmaDispatch.

The publication has been inundated with suggestions on how the Coalition has constructed the 2,100 number - one stands out.

An appointment for the GSK-Pfizer Consumer Healthcare joint venture in Australia and New Zealand with Anish Patel the new area general manager.

AstraZeneca managing director and Medicines Australia board member Liz Chatwin says the research-based industry is "so much more than just medicines".

A setback for the Pharmaceutical Society of Australia with Belinda Wood departing the organisation during negotiation of the Seventh Community Pharmacy Agreement.

The PBAC rejected a broad and simplified listing for the PDL1 inhibitor immunotherapies for lung cancer because of "varying clinical evidence" and the "absence of a compelling financial offer from any sponsor".

A new member for the Generic and Biosimilar Medicines Association with Fresenius Kabi Australia joining the association. Fresenius Kabi provides IV-generics, infusion therapies,...

Weber Shandwick is ramping up its regional healthcare practice with the appointment of an experienced industry communications and public affairs executive.